Get started
Author

Marta Roig

Observed names: M. Parera Roig, Marta Parera Roig, Marta Parera-Roig, Parera Roig, Marta
ORCID: 0000-0001-8571-4878
Observed ORCID: 0000-0001-8571-4878
OpenAlex ID: A5018342384
Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia
2024 · Marta Parera Roig, David Compte Colomé, et al. · Current Oncology · 3
PDF
Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC. Contribution of IASLC recommendations
2021 · Diego Muñoz-Guglielmetti, David Sanchez-Lorente, et al. · World Journal of Clinical Oncology · 3
97eP Predictors of recurrence and survival in endometrial cancer: A 22-year single-center cohort
2026 · E.G. Sardo, M. Alejo Sanchez, et al. · ESMO Open
PDF
158P Neoadjuvant treatment in stage III NSCLC: Comparison with NADIM 2 trial as a gold standard
2024 · F. Casas, M.G. Antelo Redondo, et al. · ESMO Open
Burden of advanced Non-small Cell lung Cancer in the Catalan Health Service (CatSalut)
2020 · Laura Guarga, Ernest Nadal, et al. · Economía de la Salud
PDF
Guía de consenso para el uso de medicamentos en insuficiencia renal
2016 · Marian March Pujol, Ma. de los Ángeles Via Sosa, et al.
Works count: 7
Citation count: 6
H-index: 2
I10-index:
Year
Topic
Type